Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 958231, 8 pages
http://dx.doi.org/10.1155/2015/958231
Research Article

Peripheral Blood Mononuclear Cell Gene Expression Remains Broadly Altered Years after Successful Interferon-Based Hepatitis C Virus Treatment

1VA Palo Alto Health Care System, Palo Alto, CA 94304, USA
2Division of Infectious Diseases & Geographic Medicine, Stanford University, Stanford, CA 94305-5107, USA

Received 12 May 2015; Revised 24 July 2015; Accepted 27 July 2015

Academic Editor: Pavel Bostik

Copyright © 2015 Paul Ravi Waldron and Mark Holodniy. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Mohd Hanafiah, J. Groeger, A. D. Flaxman, and S. T. Wiersma, “Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence,” Hepatology, vol. 57, no. 4, pp. 1333–1342, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. K. N. Ly, J. Xing, R. M. Klevens, R. B. Jiles, and S. D. Holmberg, “Causes of death and characteristics of decedents with viral hepatitis, United States, 2010,” Clinical Infectious Diseases, vol. 58, no. 1, pp. 40–49, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. K. N. Ly, J. Xing, R. M. Klevens, R. B. Jiles, J. W. Ward, and S. D. Holmberg, “The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007,” Annals of Internal Medicine, vol. 156, no. 4, pp. 271–278, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Chak, A. H. Talal, K. E. Sherman, E. R. Schiff, and S. Saab, “Hepatitis C virus infection in USA: an estimate of true prevalence,” Liver International, vol. 31, no. 8, pp. 1090–1101, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Kenny-Walsh, “Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group,” The New England Journal of Medicine, vol. 340, no. 16, pp. 1228–1233, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. D. L. Thomas, J. Astemborski, R. M. Rai et al., “The natural history of hepatitis C virus infection: host, viral, and environmental factors,” Journal of the American Medical Association, vol. 284, no. 4, pp. 450–456, 2000. View at Google Scholar · View at Scopus
  7. D. L. Thomas, C. L. Thio, M. P. Martin et al., “Genetic variation in IL28B and spontaneous clearance of hepatitis C virus,” Nature, vol. 461, no. 7265, pp. 798–801, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. M. G. Ghany, D. R. Nelson, D. B. Strader, D. L. Thomas, and L. B. Seeff, “An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases,” Hepatology, vol. 54, no. 4, pp. 1433–1444, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. M. G. Ghany, D. B. Strader, D. L. Thomas, and L. B. Seeff, “Diagnosis, management, and treatment of hepatitis C: an update,” Hepatology, vol. 49, no. 4, pp. 1335–1374, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Lawitz, A. Mangia, D. Wyles et al., “Sofosbuvir for previously untreated chronic hepatitis C infection,” The New England Journal of Medicine, vol. 368, no. 20, pp. 1878–1887, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. A. J. van der Meer, B. J. Veldt, J. J. Feld et al., “Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis,” The Journal of the American Medical Association, vol. 308, no. 24, pp. 2584–2593, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Hara, M. M. Rivera, C. Koh et al., “Sequence analysis of hepatitis c virus from patients with relapse after a sustained virological response: relapse or reinfection?” The Journal of Infectious Diseases, vol. 209, no. 1, pp. 38–45, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Radkowski, J. F. Gallegos-Orozco, J. Jablonska et al., “Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C,” Hepatology, vol. 41, no. 1, pp. 106–114, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. H. I. Mohamed, H. K. Fath El-Bab, and A. M. Kamal, “HCV RNA in serum and peripheral blood mononuclear cells after successful interferon therapy,” Hepato-Gastroenterology, vol. 58, no. 107-108, pp. 932–936, 2011. View at Google Scholar · View at Scopus
  15. T. N. Q. Pham, C. S. Coffin, N. D. Churchill, S. J. Urbanski, S. S. Lee, and T. I. Michalak, “Hepatitis C virus persistence after sustained virological response to antiviral therapy in patients with or without past exposure to hepatitis B virus,” Journal of Viral Hepatitis, vol. 19, no. 2, pp. 103–111, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Zaghloul and W. El-Sherbiny, “Detection of occult hepatitis C and hepatitis B virus infections from peripheral blood mononuclear cells,” Immunological Investigations, vol. 39, no. 3, pp. 284–291, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. R. A. Zayed, E. Rushdy, and D. A. Saleh, “Detection of HCV RNA in the peripheral blood mononuclear cells of serum HCV RNA-negative Egyptian patients under interferon treatment,” The American Journal of the Medical Sciences, vol. 340, no. 6, pp. 435–438, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Januszkiewicz-Lewandowska, J. Wysocki, M. Pernak et al., “Presence of hepatitis C virus (HCV)-RNA in peripheral blood mononuclear cells in HCV serum negative patients during interferon and ribavirin therapy,” Japanese Journal of Infectious Diseases, vol. 60, no. 1, pp. 29–32, 2007. View at Google Scholar · View at Scopus
  19. A. Y. Chen, M. Zeremski, R. Chauhan, I. M. Jacobson, A. H. Talal, and T. I. Michalak, “Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis C with standard pegylated interferon α-2b and ribavirin therapy,” PLoS ONE, vol. 8, no. 11, Article ID e80078, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Bernardin, L. Tobler, I. Walsh, J. D. Williams, M. Busch, and E. Delwart, “Clearance of hepatitis C virus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia,” Hepatology, vol. 47, no. 5, pp. 1446–1452, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Fujiwara, R. D. Allison, R. Y. Wang et al., “Investigation of residual hepatitis C virus in presumed recovered subjects,” Hepatology, vol. 57, no. 2, pp. 483–491, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. L. E. Kushner, A. M. Wendelboe, L. C. Lazzeroni et al., “Immune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients,” PLoS ONE, vol. 8, no. 4, Article ID e60387, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. G. M. Sousa, I. S. Oliveira, L. J. O. Andrade, M. L. B. Sousa-Atta, R. Paraná, and A. M. Atta, “Serum levels of Th17 associated cytokines in chronic hepatitis C virus infection,” Cytokine, vol. 60, no. 1, pp. 138–142, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. T. N. Q. Pham, S. E. Mercer, and T. I. Michalak, “Chronic hepatitis C and persistent occult hepatitis C virus infection are characterized by distinct immune cell cytokine expression profiles,” Journal of Viral Hepatitis, vol. 16, no. 8, pp. 547–556, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Radkowski, J. Opoka-Kegler, K. C. Cortes et al., “Evidence for immune activation in patients with residual hepatitis C virus RNA long after successful treatment with IFN and ribavirin,” The Journal of General Virology, vol. 95, no. 9, pp. 2004–2009, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. A. K. Barcz, J. E. Gomez, B. B. Kaufmann et al., “RNA signatures allow rapid identification of pathogens and antibiotic susceptibilities,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 16, pp. 6217–6222, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. J. J. Chang, M. Woods, R. J. Lindsay et al., “Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication,” The Journal of Infectious Diseases, vol. 208, no. 5, pp. 830–838, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Vallet-Pichard, V. Mallet, B. Nalpas et al., “FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest,” Hepatology, vol. 46, no. 1, pp. 32–36, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. M. E. Charlson, P. Pompei, K. L. Ales, and C. R. MacKenzie, “A new method of classifying prognostic comorbidity in longitudinal studies: development and validation,” Journal of Chronic Diseases, vol. 40, no. 5, pp. 373–383, 1987. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Hess, P. Angel, and M. Schorpp-Kistner, “AP-1 subunits: quarrel and harmony among siblings,” Journal of Cell Science, vol. 117, no. 25, pp. 5965–5973, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. K. A. Fitzgerald, E. M. Palsson-Mcdermott, A. G. Bowie et al., “Mal (MyD88-adapter-like) is required for toll-like recepfor-4 signal transduction,” Nature, vol. 413, no. 6851, pp. 78–83, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Saraiva and A. O'Garra, “The regulation of IL-10 production by immune cells,” Nature Reviews Immunology, vol. 10, no. 3, pp. 170–181, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. W. Glenisson, V. Castronovo, and D. Waltregny, “Histone deacetylase 4 is required for TGFβ1-induced myofibroblastic differentiation,” Biochimica et Biophysica Acta—Molecular Cell Research, vol. 1773, no. 10, pp. 1572–1582, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. M. T. Dill, Z. Makowska, G. Trincucci et al., “Pegylated IFN-α regulates hepatic gene expression through transient Jak/STAT activation,” The Journal of Clinical Investigation, vol. 124, no. 4, pp. 1568–1581, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. J. L. Casado, M. A. Esteban, S. Bañón et al., “Fibrosis regression explains differences in outcome in HIV-/HCV-coinfected patients with cirrhosis after sustained virological response,” Digestive Diseases and Sciences, 2015. View at Publisher · View at Google Scholar
  36. H. W. Zimmermann, S. Seidler, N. Gassler et al., “Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis,” PLoS ONE, vol. 6, no. 6, Article ID e21381, 2011. View at Publisher · View at Google Scholar · View at Scopus